Sol-Gel Tech (SLGL) has released an update.
Sol-Gel Technologies announces its partner Padagis’s submission of an ANDA for a generic version of Zoryve® Cream, which treats plaque psoriasis and has a potential market exclusivity period of 180 days upon FDA approval. The market sales for Zoryve Cream were approximately $95 million over the past year, with analysts projecting over $500 million in net revenue by 2030, indicating a significant market opportunity for Sol-Gel and Padagis.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
